MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

4.77 4.38

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.77

Max

4.77

Galvenie mērījumi
By Trading Economics
Ienākumi	259K -1.5M
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	260K -1.5M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.9M 18M
Iepriekšējā atvēršanas cena	0.39
Iepriekšējā slēgšanas cena	4.77

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. okt. 18:13 UTC

Galvenie tirgus virzītāji

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

2025. g. 17. okt. 17:05 UTC

Galvenie tirgus virzītāji

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

2025. g. 17. okt. 15:03 UTC

Galvenie tirgus virzītāji

Obook Shares Sink Following Public Debut

2025. g. 17. okt. 14:41 UTC

Galvenie tirgus virzītāji

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

2025. g. 17. okt. 23:25 UTC

Iegādes, apvienošanās, pārņemšana

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

2025. g. 17. okt. 22:15 UTC

Tirgus saruna

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

2025. g. 17. okt. 21:15 UTC

Tirgus saruna

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

2025. g. 17. okt. 21:07 UTC

Tirgus saruna

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

2025. g. 17. okt. 21:07 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 17. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. okt. 20:34 UTC

Tirgus saruna

Deere Is Reaching the End of Its Downcycle -- Market Talk

2025. g. 17. okt. 20:27 UTC

Tirgus saruna

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

2025. g. 17. okt. 19:46 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 17. okt. 19:45 UTC

Tirgus saruna

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

2025. g. 17. okt. 18:45 UTC

Tirgus saruna

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

2025. g. 17. okt. 17:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. okt. 17:51 UTC

Tirgus saruna

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

2025. g. 17. okt. 17:44 UTC

Tirgus saruna

EQT Seen With Long-Term Growth Opportunities -- Market Talk

2025. g. 17. okt. 17:35 UTC

Tirgus saruna

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

2025. g. 17. okt. 16:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 17. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. okt. 16:14 UTC

Tirgus saruna

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

2025. g. 17. okt. 16:04 UTC

Tirgus saruna

Home Improvement Demand Is Starting to Pick Up -- Market Talk

2025. g. 17. okt. 15:58 UTC

Tirgus saruna

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

2025. g. 17. okt. 15:56 UTC

Peļņas

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

2025. g. 17. okt. 15:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 17. okt. 15:43 UTC

Tirgus saruna

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

2025. g. 17. okt. 14:58 UTC

Tirgus saruna

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

2025. g. 17. okt. 14:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. okt. 14:35 UTC

Tirgus saruna

Peļņas

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.